ArticleAnnals of hematology2026
Vitamin D deficiency in sickle cell disease: a neglected comorbidity in Tunisia.
Article in Annals of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Vitamin D Deficiency as a Potential Modifier of Hematological Outcomes and Vaso-Occlusive Crisis Frequency in Sickle Cell Disease: Evidence from a Sudanese Cohort.Biomedicines · 2026Article
- Vitamin D Deficiency and Its Hematological Correlates in Patients with Sickle Cell Disease at a Ugandan Clinic.Journal of blood medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sickle cell disease (SCD) is a hereditary hemoglobinopathy that imposes a significant burden on global health. Individuals with SCD often experience multiple nutritional deficiencies, among which vitamin D deficiency has emerged as a critical yet under recognized factor contributing to disease complications. This study aimed to assess the vitamin D status in patients with SCD compared to a matched healthy control group, and to explore its correlation with clinical and biological parameters, including the frequency of vaso-occlusive crises (VOC). A cross-sectional study was conducted between January and June 2024 at Bechir Hamza Children's Hospital, Tunis. Sixty-four SCD patients and 63 healthy controls were enrolled. Vitamin D [25(OH)D] levels, along with hematologic and biochemical markers, were measured. Statistical analyses included t-tests, chi-square test, ANOVA, and Spearman correlation. Vitamin D levels were significantly lower in the SCD group (15.05 ± 6.6 ng/mL) compared to controls (22.51 ± 12.54 ng/mL, p = 0.026). Among SCD patients, 78.2% (50) had Vitamin D deficiency (< 20ng/mL), 20.3% (13) had Vitamin D insuffisancy (20-30 ng/mL) and only one patient (1.5%) had normal vitamin D status (> 30 ng/mL). Vitamin D levels were inversely correlated with age, total bilirubin, parathyroid hormone (PTH), and frequency of VOC, and positively correlated with hemoglobin concentration and socioeconomic status. SCD patients with vitamin D deficiency experienced significantly more VOC episodes per year. Vitamin D deficiency is highly prevalent among SCD patients and is associated with increased disease severity. Routine screening and appropriate supplementation should be considered as part of comprehensive SCD management strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.